KRAS G12D Mutation Clinical Trials in Nanjing
2 recruitingNanjing, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer
Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
The First Affiliated Hospital with Nanjing Medical University30 enrolled1 locationNCT07438106
Recruiting
Phase 2
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Pancreatic Ductal Adenocarcinoma (PDAC)KRAS G12D Mutations
Ranok Therapeutics (Hangzhou) Co., Ltd.60 enrolled2 locationsNCT07303465